Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avecia Biotechnology, a provider of drug development and manufacturing services for oligonucleotide therapeutics, has reached an agreement with Pfizer regarding the commercial supply of a key component of Macugen (pegaptanib sodium injection), marketed in the EU by Pfizer for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Subscribe to our email newsletter
Pegaptanib sodium injection is an anti-angiogenic medicine for the treatment of neovascular (wet) AMD. It was discovered by Gilead Sciences and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the US.
Avecia Biotechnology said that the agreement includes technology transfer, process validation and commercial supply of a key component of Macugen.
Detlef Rethage, president of Avecia Biotechnology, said: “The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our experience, reliability and quality standards with regard to technology transfer, process validation and the manufacture of oligonucleotide drug substances.”